YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
96 hedge funds and large institutions have $126M invested in Y-mAbs Therapeutics in 2025 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 36 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
6% less funds holding
Funds holding: 102 → 96 (-6)
22% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 36
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
Holders
96
Holding in Top 10
1
Calls
$151K
Puts
$2K
Top Buyers
| 1 | +$1.59M | |
| 2 | +$828K | |
| 3 | +$746K | |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$695K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$620K |
Top Sellers
| 1 | -$1.96M | |
| 2 | -$1.47M | |
| 3 | -$936K | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$904K |
| 5 |
BlackRock
New York
|
-$694K |
